Drug intelligence / Profile preview

3D125

Development stage: Preclinical
Lead developer: 3D Medicines
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Injection

Overview

3D125 is an investigational mRNA-based cancer vaccine being developed by 3D Medicines for the treatment of small cell lung cancer (SCLC). The vaccine is designed to deliver mRNA encoding specific tumor-associated antigens to the patient's cells, which then express these antigens to stimulate a targeted antitumor immune response. By training the immune system to recognize and attack SCLC cells, 3D125 aims to provide a novel therapeutic option for this aggressive malignancy. As of the latest reports, the drug is in the preclinical stage of development.

Beyond the preview

Go deeper on 3D125.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3D125.

Explore the full profile